Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Spirent Communications 'tracking to plan' after Q1 performance

(Sharecast News) - Telecommunications testing company Spirent Communications said on Wednesday that its performance was "tracking to plan" as it issued a trading update for the three months ended 31 March. Spirent Communications said it has continued to "manage global market challenges and engage closely" with its customers, noting that Q1 orders and revenue were both in line with its plan and the same period a year earlier.

In the first quarter, the AIM-listed group said its positioning business won "an industry first contract", utilising new IP to simulate the lunar environment. While Spirent said it saw "some slight delays" for its assurance solutions, this was offset by "strong demand" for high-speed ethernet due to growing demand for 800G, its new AI solution and support for data centre builds.

"We are carefully reviewing tariff changes and, as they come into effect, we will take mitigating actions, including customer surcharges and logistical changes to our global sourcing and delivery routes. We will continue to monitor any potential impacts on customer buying patterns and order timings," added the FTSE 250-listed firm

As of 1000 BST, Spirent shares were down 0.11% at 184.80p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.